Immunotherapy combo shows promise for Hard-to-Treat ovarian cancer
NCT ID NCT03026062
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase II trial tested two immunotherapy drugs, durvalumab and tremelimumab, in 100 women with ovarian, fallopian tube, or peritoneal cancer that had come back or stopped responding to platinum-based chemotherapy. The study compared giving the drugs together versus one after the other to see which approach works better. The goal was to delay cancer growth by boosting the immune system's ability to attack tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab and tremelimumab (immunotherapy drugs)
What this could lead to
If successful, this could point toward a new treatment option for women with ovarian cancer that has stopped responding to standard chemotherapy.
What could go wrong
This is a small, early-phase trial (100 participants) with no control group, so results may not lead to a proven therapy. Immunotherapy can cause serious side effects like inflammation of organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States